Edition:
India

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

22.12USD
2:29am IST
Change (% chg)

$-1.25 (-5.35%)
Prev Close
$23.37
Open
$23.15
Day's High
$23.15
Day's Low
$21.56
Volume
439,384
Avg. Vol
284,536
52-wk High
$108.50
52-wk Low
$17.62

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.15
Market Cap(Mil.): $891.21
Shares Outstanding(Mil.): 38.13
Dividend: --
Yield (%): --

Financials

Puma Biotech gets EU panel nod for breast cancer drug

Puma Biotechnology Inc  on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

29 Jun 2018

Puma Biotech gets EU panel nod for breast cancer drug

June 29 Puma Biotechnology Inc on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it.

29 Jun 2018

Puma Biotech says Europe likely to approve breast cancer drug

Puma Biotechnology Inc said on Tuesday a committee of the European Medicines Agency was likely to give positive opinion on its breast cancer drug, five months after the regulator recommended against approving it.

26 Jun 2018

Former Puma Biotech exec gets U.S. prison term for insider trading

BOSTON, June 20 A former Puma Biotechnology Inc executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing.

21 Jun 2018

Earnings vs. Estimates